MARKET

CYCC

CYCC

Cyclacel Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.388
+0.038
+2.78%
Opening 14:57 05/19 EDT
OPEN
1.380
PREV CLOSE
1.350
HIGH
1.400
LOW
1.370
VOLUME
55.36K
TURNOVER
59.19K
52 WEEK HIGH
7.95
52 WEEK LOW
1.290
MARKET CAP
13.87M
P/E (TTM)
-0.6512
1D
5D
1M
3M
1Y
5Y
Cyclacel Pharmaceuticals: Q1 Earnings Insights
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 05/11 21:17
Cyclacel Pharmaceuticals GAAP EPS of -$0.42 beats by $0.27
Cyclacel Pharmaceuticals press release (NASDAQ:CYCC): Q1 GAAP EPS of -$0.42 beats by $0.27. As of March 31, 2022, cash and cash equivalents totaled $29.6 million, compared to $36.6 million as
Seekingalpha · 05/11 20:16
Cyclacel Pharmaceuticals Q1 EPS $(0.42) Beats $(0.68) Estimate
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.68) by 38.24 percent. This is a 16 percent increase over losses of $(0.50) per share
Benzinga · 05/11 20:13
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
Cyclacel Pharmaceuticals's Earnings Outlook
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Cyclacel Pharmaceuticals will report an earnings per sha...
Benzinga · 05/10 16:37
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce firs...
GlobeNewswire · 05/04 13:15
BRIEF-Cyclacel Doses First Patient In Phase 1/2 Study Of Oral CYC140
reuters.com · 04/19 13:19
More
No Data
Learn about the latest financial forecast of CYCC. Analyze the recent business situations of Cyclacel Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CYCC stock price target is 19.33 with a high estimate of 24.00 and a low estimate of 17.00.
High24.00
Average19.33
Low17.00
Current 1.400
EPS
Actual
Estimate
-0.54-0.41-0.27-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 34
Institutional Holdings: 3.27M
% Owned: 32.74%
Shares Outstanding: 9.99M
TypeInstitutionsShares
Increased
7
334.90K
New
5
43.31K
Decreased
6
233.11K
Sold Out
4
596.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Christopher Henney
President/Chief Executive Officer/Director
Spiro Rombotis
Chief Financial Officer/Chief Operating Officer/Executive Vice President - Finance/Secretary/Director
Paul Mcbarron
Senior Vice President
Mark Kirschbaum
Independent Director
Samuel Barker
Independent Director
Gregory Hradsky
Independent Director
Brian Schwartz
Independent Director
Lloyd Sems
Independent Director
Robert Spiegel
Independent Director
Karin Walker
No Data
No Data
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The Company is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The Company's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The Company's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCC stock methods without spending real money on the virtual paper trading platform.